Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYLK | Q15746 | 10/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | PRKCG | P05129 | 1/20 | 1.00 |
| ▸ | PRKCB | P05771 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8953712 | 1.00 | MYLK (1.00) | MYLKROCK2PLK4AURKAPDPK1 | |
| Go-6976 SCHEMBL29356928 | 1.00 | MYLK (1.00) | MYLKROCK2PLK4AURKAPDPK1 | |
| Go-6976 SCHEMBL29357848 | 1.00 | MYLK (1.00) | MYLKROCK2PLK4AURKAPDPK1 | |
| SCHEMBL9544983 | 0.92 | MYLK (0.85) | MYLKROCK2PLK4AURKAPDPK1 | |
| SCHEMBL9544982 | 0.87 | MYLK (0.78) | MYLKROCK2PLK4AURKAPDPK1 | |
| SCHEMBL9544956 | 0.87 | MYLK (0.78) | MYLKROCK2PLK4AURKAPDPK1 | |
| SCHEMBL9544938 | 0.86 | MYLK (1.00) | MYLKROCK2PLK4AURKAPDPK1 | |
| SCHEMBL14040741 | 0.86 | MYLK (0.88) | MYLKROCK2PLK4AURKAPDPK1 | |
| SCHEMBL9200017 | 0.85 | MYLK (0.74) | MYLKROCK2PLK4AURKAPDPK1 | |
| SCHEMBL8115236 | 0.85 | MYLK (1.00) | MYLKROCK2PLK4AURKAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152531-A1 | INHIBITORS OF AUTOPHAGY AND DCAR-1 AS NOVEL ANTHELMINTIC AGENTS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES | 2025-05-15 | — | — | US | claimed |
| US-12233036-B2 | Inhibitors of autophagy and DCAR-1 as novel anthelmintic agents | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2025-02-25 | — | — | US | claimed |
| US-20230414672-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DEGENERATIVE BRAIN DISEASE, INCLUDING NEURAL PRECURSOR CELLS DERIVED FROM PLURIPOTENT STEM CELLS | SBIOMEDICS (KR) | 2023-12-28 | — | — | US | claimed |
| EP-4241777-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DEGENERATIVE BRAIN DISEASE, INCLUDING NEURAL PRECURSOR CELLS DERIVED FROM PLURIPOTENT STEM CELLS | SBIOMEDICS (KR) | 2023-09-13 | — | — | EP | claimed |
| US-9446043-B2 | Pharmaceutical combinations | NOVARTIS AG (CH) | 2016-09-20 | — | — | US | claimed |
| US-20150306101-A1 | Pharmaceutical Combinations | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2925366-A1 | PHARMACEUTICAL COMBINATIONS | Novartis AG (CH) | 2015-10-07 | — | — | EP | claimed |
| WO-2014174478-A1 | PHARMACEUTICAL COMBINATIONS OF A PKC INHIBITOR AND A C-MET RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2014-10-30 | — | — | WO | claimed |
| WO-2014085381-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2014-06-05 | — | — | WO | claimed |
| WO-2014081922-A1 | COMPOSITIONS AND METHODS USEFUL IN PREVENTING AND TREATING APICOMPLEXA INFECTIONS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-05-30 | — | — | WO | claimed |
| WO-2009016629-A2 | PHARMACEUTICAL COMPOSITION FOR TREATING WOUNDS AND RELATED METHODS | HEALOR LTD. (IL) | 2009-02-05 | — | — | WO | claimed |
| US-20080009511-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2008-01-10 | — | — | US | claimed |
| EP-1416929-A4 | CANCER TREATMENT WITH GÖ6976 AND ITS RELATED COMPOUNDS | LU ZHIMIN (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060009492-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2006-01-12 | — | — | US | claimed |
| EP-1416929-A2 | CANCER TREATMENT WITH GÖ6976 AND ITS RELATED COMPOUNDS | Lu, Zhimin (US) | 2004-05-12 | — | — | EP | claimed |
| WO-2003009809-A2 | CANCER TREATMENT WITH GÖ6976 AND ITS RELATED COMPOUNDS | LU ZHIMIN (US) | 2003-02-06 | — | — | WO | claimed |
| US-20020016352-A1 | Cancer treatment with Go6976 and its related compounds | LU ZHIMIN (US) | 2002-02-07 | — | — | US | claimed |
| EP-0434057-B1 | Indolocarbazole derivatives, processes for their preparation and their use | GOEDECKE AG (DE) | 1996-07-31 | — | — | EP | claimed |
| WO-1993024490-A1 | USE OF INDOLOCARBAZOLS IN AIDS TREATMENT | Gödecke Aktiengesellschaft (DE) | 1993-12-09 | — | — | WO | claimed |
| EP-0434057-A2 | Indolocarbazole derivatives, processes for their preparation and their use | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1991-06-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009511-A1 | Cancer treatment with compounds inhibiting PKC alpha | PRKCE, ROCK1, PRKCA | MYLK 1440/4885ROCK2 16/4885PLK4 513/4885 |
| US-20020016352-A1 | Cancer treatment with Go6976 and its related compounds | GRK6, GALK1, PRKACA | MYLK 1026/4885ROCK2 51/4885PLK4 1057/4885 |
| US-20150306101-A1 | Pharmaceutical Combinations | MAP2K1, PRKACA, MAP2K2 | MYLK 156/4885ROCK2 185/4885PLK4 412/4885 |
| US-20060009492-A1 | Cancer treatment with compounds inhibiting PKC alpha | PRKCE, ROCK1, PRKCA | MYLK 1440/4885ROCK2 16/4885PLK4 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.